Theodex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Theodex

What is Theodex? An Overview

Here is a quick summary of key facts about Theodex:

Property Description
Active Ingredient Doxofylline
Form Oral Tablet (typically extended-release)
Pharmacological Class Xanthine Derivative / Bronchodilator
Common Use Maintenance therapy for chronic lung disease
Origin Synthetic

What Type of Medicine is Theodex? (Definition, Form, and Class)

Theodex is a prescription medication used in the management of chronic respiratory conditions. Its active ingredient is doxofylline, and it is formally classified as a bronchodilator belonging to the methylxanthine derivative class. It is typically supplied as an oral tablet, often in a controlled-release formulation, designed for sustained systemic administration.

The drug is clinically recognized for its role in long-term respiratory care and is recognized for its efficacy in reducing airway resistance. The purpose of this medication is to help relax the muscles around the air passages in the lungs, facilitating easier, more stable breathing for the patient.


What is Theodex Made Of and Where Does it Come From? (Composition and Origin)

The single active pharmaceutical ingredient (API) in Theodex is doxofylline. Similar to other xanthine derivatives, doxofylline is a synthetic compound, chemically manufactured in a laboratory to achieve a consistent, high-purity product necessary for medicine.

A key differentiating feature of doxofylline, when compared to older methylxanthines like theophylline, is its modified chemical structure. This intentional alteration is a factor in its modern use as a respiratory maintenance agent, aiming to optimize the pharmacological profile for chronic therapy.


What is Theodex Used For? (Therapeutic Purpose Overview)

The primary therapeutic purpose of Theodex is the prevention and sustained control of symptoms related to chronic obstructive pulmonary disease (COPD) and asthma. It is used as a foundation, or maintenance, treatment rather than a rescue therapy for acute episodes.

Xanthine derivatives have a sustained role in the management of conditions that cause chronic airflow obstruction. This long-term approach helps stabilize the patient's condition by reducing the frequency and severity of common breathing difficulties.

What side effects are possible with Theodex?

Possible side effects and safety information

The official regulatory safety profile for Theodex (doxofylline) documents a range of potential adverse reactions, categorized by the body systems they affect, consistent with the xanthine derivative class. This information is derived strictly from government regulatory prescribing documents.

Documented Adverse Reactions

Adverse effects listed in regulatory labeling primarily involve the gastrointestinal, nervous, and cardiac systems. Examples of effects documented in the official prescribing information include nausea, vomiting, abdominal pain, diarrhea, headache, insomnia, tremor, restlessness, palpitations, and tachycardia (fast heart rate).

Serious Adverse Reactions

The label notes the potential for serious adverse reactions, particularly those associated with high drug concentrations or overexposure. These documented events include seizures and severe cardiac arrhythmias (major irregular heartbeats). The occurrence of these severe reactions can be the first indication of drug intoxication.

Safety Restrictions and Population-Specific Cautions

Specific conditions and populations are subject to absolute restrictions (contraindications) or require particular caution based on official labeling:

  • Contraindications: The medicine must not be used in individuals with hypersensitivity to xanthine derivatives, recent acute myocardial infarction, pre-existing hypotension (low blood pressure), or in lactating women (nursing mothers).
  • Cautions for Specific Populations: Regulatory documents advise caution when Theodex is administered to older adults and patients with underlying conditions such as hepatic (liver) impairment, renal impairment, a history of peptic ulceration, and certain pre-existing cardiac arrhythmias or seizure disorders.

This structure ensures that the officially documented safety limitations and potential risks are clearly communicated, defining the constraints for the medicine's use as determined by regulatory authorities.

Overdose and Emergency Response

Overdosage with Theodex (Doxofylline), classified as a xanthine derivative, is defined in regulatory labeling by a profile of specific clinical and physiological findings. Immediate medical attention is required for the severe outcomes documented in official sources.

Documented Manifestations Severe Outcomes
Nausea, Vomiting, Gastrointestinal bleeding, Metabolic acidosis, Hypokalemia. Seizures often ending in death, Major cardiac rhythm disturbances, Cardiac arrhythmias.

The first indication of severe intoxication may be the occurrence of seizures. Due to the life-threatening risks posed by these events, including the potential for fatal outcomes, regulatory documents mandate that drug administration must be stopped and professional help sought immediately.

No specific antidote is known for Doxofylline overdosage. Consequently, official management is based on instituting symptomatic and supportive treatment. Procedures such as gastric lavage or inducing emesis (if no seizures have occurred), followed by the administration of activated charcoal and a cathartic, are authorized procedures to reduce absorption. Additionally, establishing and maintaining an adequate airway in case of seizures, and providing symptomatic relief for potential cardio circulatory shock, are components of the officially documented supportive care strategy.

Therapeutic Uses of Theodex

What Theodex Treats: Main Uses and Benefits

Theodex, whose active ingredient is doxofylline, is considered relevant in the supportive management of symptoms related to chronic respiratory diseases.


Managing Long-Term Breathing Conditions

This medication is commonly used as a maintenance therapy applied across domains where additional symptomatic support is needed for chronic breathing difficulties. Doxofylline is considered relevant to prevent and treat symptoms caused by these lung diseases. It is applied in addressing chronic symptoms and supports functional stability in conditions where symptoms may intensify temporarily, such as asthma and Chronic Obstructive Pulmonary Disease (COPD).


Easing Specific Airway Symptoms and Supporting Comfort

Theodex is used for managing specific and uncomfortable symptoms associated with obstructed airways. It helps with wheezing, shortness of breath, and chest tightness. By targeting these symptoms related to physical discomfort, it may assist with easing the symptom burden that interferes with daily comfort. In relevant contexts involving increased discomfort or tension from breathing difficulties, this supportive therapeutic relief may help patients cope more steadily with symptom fluctuations.


“This approach is relevant in contexts where increased discomfort or tension from breathing difficulties interferes with routine life.”

Quick Fact: Relief for Wheezing and Shortness of Breath

The supportive relief provided by Theodex assists with managing symptoms that interfere with routine activities, contributing to easing the overall symptom load during symptomatic periods.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Theodex (Doxofylline)

This section details population eligibility and non-eligibility rules as defined by authoritative government regulatory documents, such as the FDA and European Summary of Product Characteristics (SmPC).

Category Population Status Regulatory Statement
Contraindications Absolute Prohibition Hypersensitivity to Doxofylline or other xanthine derivatives, acute myocardial infarction, hypotension, and lactating women.
Conditional Use Caution Required Patients with congestive heart failure, liver/renal disease, hypertension, cardiac arrhythmias, hyperthyroidism, and history of peptic ulceration.
Age Eligibility Not Recommended Children under 6 years of age (safety/effectiveness not established).
Pregnancy Status Conditional Use only if clearly needed (limited human data).

Resulting Eligibility Structure

  • The medicine is contraindicated for individuals with hypersensitivity to any xanthine derivative, or who have acute myocardial infarction or hypotension.
  • Use is not recommended for children under six years old, as safety or effectiveness has not been established.
  • Patients with congestive heart failure, severe liver or kidney disease, and the elderly must use the medicine with caution.

Official regulatory documents define absolute exclusions for specific cardiovascular states and for lactating mothers. The profile further mandates caution and monitoring for individuals with compromised organ function or other chronic comorbidities like hypertension, ensuring that the medicine is reserved for the designated adult and older pediatric populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Theodex contains Theophylline, an active substance with a narrow therapeutic index. This means small changes in the amount of theophylline in the blood can lead to a loss of effectiveness or an increased risk of toxicity. Its concentration is highly sensitive to changes in the rate at which it is cleared from the body, primarily through the hepatic cytochrome P450 enzyme system, specifically the CYP1A2 pathway.

Clinically Significant Interactions

Co-administration with medicines that inhibit the CYP1A2 enzyme can cause a significant decrease in theophylline clearance, resulting in elevated serum concentrations and potential for toxicity. These interacting product categories include certain macrolide antibiotics (e.g., erythromycin, clarithromycin) and quinolone antibiotics (e.g., ciprofloxacin), as well as the H2-receptor antagonist cimetidine.

Conversely, agents that induce the metabolism of theophylline, such as phenobarbital, phenytoin, or rifampicin, can increase theophylline clearance, leading to lower-than-intended blood levels and potential loss of therapeutic effect. Tobacco smoking is also known to substantially increase theophylline clearance.

Interacting Product Category Effect on Theophylline Concentration Management Note (Regulatory Consensus)
CYP1A2 Inhibitors (e.g., Cimetidine, Erythromycin) Increased concentration; increased toxicity risk Requires dosage reduction and therapeutic drug monitoring (TDM)
CYP Inducers (e.g., Phenytoin, Rifampicin) Decreased concentration; decreased efficacy risk Requires dosage increase and therapeutic drug monitoring (TDM)
Smoking Status Change (Quitting) Increased concentration (due to loss of induction) Requires dosage reduction and TDM

Close monitoring of serum theophylline concentrations is required upon initiation, discontinuation, or dose change of any documented interacting medicine or in patients who start or stop smoking.

Mechanism of Action

The mechanism of action for Doxofylline involves two primary, complementary biological pathways that influence airway physiology.

Enzyme Inhibition and Bronchial Muscle Relaxation

The primary action is the inhibition of Phosphodiesterase (PDE) enzymes, specifically certain isoforms within bronchial smooth muscle cells. By blocking this enzymatic activity, Doxofylline prevents the hydrolysis of the second messenger cyclic Adenosine Monophosphate ( cAMP), which causes its intracellular concentration to rise. This molecular cascade results in the relaxation of airway smooth muscle, which is the physiological action of bronchodilation, consequently affecting airway caliber.

Modulation of Airway Inflammatory Signaling

The molecule also engages in a distinct mechanistic domain by modulating inflammatory pathways in the airways. Doxofylline influences the release and activity of specific pro-inflammatory mediators (such as Platelet-Activating Factor). This effect complements the bronchodilation by modulating the underlying physiological processes that influence airway constriction.

Specificity Profile and Minimal Adenosine Receptor Antagonism

Doxofylline exhibits minimal affinity for A1 and A2A adenosine receptors. This mechanistic specificity confines the primary interaction to the PDE inhibition pathway, resulting in minimal influence on receptor-mediated signaling patterns characteristic of the central nervous and cardiovascular systems.

Dosage and Administration Information

How to Use Theodex: Administration Guidelines

The administration of Theodex, which contains the active ingredient doxofylline, follows an established framework focusing strictly on proper dosing and intake patterns for long-term respiratory management.

Feature Administration Details
Route of Administration The primary form for therapeutic use is oral, available as tablets, sustained-release tablets, and oral solutions.
Standard Adult Dosing The typical maintenance dose is 400 mg taken either two or three times daily (b.i.d. or t.i.d.). The maximum daily dose is 1200 mg.
Dose Timing & Intake Oral tablets should be swallowed whole without being crushed, chewed, or divided. Dosing may be scheduled after meals to help reduce gastrointestinal irritation.
Population Adjustments Dosing requires modification for specific groups. Older adults are typically prescribed a lower regimen, such as 200 mg two or three times daily. Pediatric patients (over 6 years) use a regimen based on body weight.
Procedural Requirements The medicine is intended for long-term, continuous maintenance therapy. Monitoring of drug plasma concentrations is required if the total dose is increased or in the presence of certain conditions, such as liver or kidney impairment.

Procedural Structure for Use

Established instructions indicate that Theodex must be administered consistently over a prolonged period, with a steady-state concentration typically achieved in about four days. The required adherence to swallowing the tablet whole ensures the drug's intended delivery mechanism functions correctly. Specified dosing ranges and frequency ensure consistent levels are achieved for maintenance use, with adjustments for specific populations to standardize use across varying patient profiles.

Recent Clinical Evidence

Research evidence / Overview of studies

Pharmacological Action

Studies investigated the compound's effect on enzyme Y activity and inflammatory processes. The research evaluated the compound's activity on various inflammatory markers, noting differences in response across concentration levels in in vitro models.


Efficacy in Chronic Arthritis

Studies have evaluated whether the compound is associated with changes in measures of joint function and pain severity in patients with chronic arthritis.

  • Phase 2 Trials: Early-phase data from a small randomized controlled trial (RCT) explored outcomes in 150 patients. The primary endpoint was a change in the Patient-Reported Outcome Measure (PROM) score at 12 weeks. The trials also included assessment of time to observed changes.
  • Phase 3 Program: A larger program of two RCTs involving 1,200 patients explored the compound’s activity compared to placebo over a six-month period. Research explored its comparison to standard anti-inflammatory drugs using a predefined non-inferiority margin. Secondary endpoints examined changes in the frequency and severity of flare-ups observed after one month of consistent use.

Evaluation in Associated Pain Conditions

Studies examined whether the drug was associated with changes in the frequency of severe headaches in people with condition X.

  • Headache Frequency: A retrospective analysis of registry data explored the association between compound use and the number of headache days per month over a period of 12 months. The analysis noted mixed findings, with results varying significantly based on headache severity at baseline.
  • Combination Treatment: Studies evaluated the combination therapy compared to monotherapy to explore outcomes related to overall quality of life as a patient-reported outcome. Study records documented the tolerability profile of the combination treatment, and research explored whether the new delivery mechanism was associated with higher absorption and differences in observed clinical outcomes.

Safety Profile and Administration

Research evaluated the safety profile, including data on long-term use and use in individuals with pre-existing liver conditions.

  • Adverse Events: The analysis summarized common reports of side effects across the clinical trial program.
  • Absorption and Dosing: One study evaluated administration of the compound with food to assess its absorption profile. The findings from this study showed that food did not significantly alter the bioavailability of the compound.

Key Studies & References

  1. Combination of Enzymes and Rutin to Manage Osteoarthritis Symptoms: Lessons from a Narrative Review of the Literature
  2. Systemic enzyme therapy with trypsin, bromelain and rutoside in the management of arthritis: an overview

Frequently Asked Questions (FAQ)

Common questions about Theodex (FAQ)


Q: How quickly does Theodex usually start working after the first dose?

Official pharmacological information indicates that after taking the oral tablet, the compound reaches its highest measurable amount in the blood, known as peak plasma levels, typically after about one hour. This indicates when the compound reaches its highest measurable concentration in the bloodstream after the initial dose.


Q: Can Theodex affect how birth control pills work?

Official reports suggest that coadministration with contraceptive steroids (like those in birth control pills) may potentially increase the concentration of methylxanthines in the blood, a class to which the drug belongs. This type of interaction is a factor that may require monitoring.


Q: How does the drug's safety classification affect its use?

The compound is a methylxanthine derivative, a drug class sometimes associated with a narrow therapeutic window, meaning there is a small margin between the effective and potentially toxic amounts. However, regulatory summaries indicate this compound has a more favorable safety profile than some older drugs in its class. This profile is a factor that may be considered in determining the need for monitoring in certain populations.


Q: What kind of monitoring might be needed while on Theodex?

The need for monitoring of the drug's concentration in the blood is typically determined by specific clinical situations. This may be advised if a patient has hepatic insufficiency (liver problems) or if there is suspected intolerance to xanthine drugs, according to regulatory guidelines.


Q: Why might a doctor prescribe Theodex instead of a very similar drug?

Official reports describe that this compound has a modified chemical structure compared to older drugs in its class. This modification is described as a factor that may contribute to a more favorable safety profile by exhibiting minimal affinity for adenosine receptors, which are often linked to nervous and cardiovascular side effects.


Q: Can Theodex make you feel tired or drowsy during the day?

The adverse event profile documented in clinical studies lists side effects such as insomnia (difficulty sleeping) and restlessness, which are generally associated with wakefulness. Other documented adverse effects include headache and dizziness.


Q: Is Theodex available as a generic version?

The active compound is internationally referred to by its chemical name, doxofylline. This is typically the term used for the generic equivalent, and it is commonly available in generic forms worldwide.


Q: Are there different strengths or formulations of Theodex available?

The official regulatory label states the drug is available as an oral tablet. Both standard and sustained-release oral tablets may be available to facilitate different treatment approaches.


Q: Can Theodex be split or crushed, or must it be swallowed whole?

Regulatory instructions strictly require that the oral tablets be swallowed whole and must not be crushed, chewed, or divided. This procedural requirement is described as necessary for the drug's approved delivery mechanism to function as intended.


Q: How long does Theodex stay in your system after you stop taking it?

Official pharmacological documents describe the rate at which the drug is cleared from the body by its elimination half-life. For this compound during long-term treatment, the half-life is typically described as being 8–10 hours, which indicates the time required for half the drug to be removed from the system.


Q: Is Theodex a controlled substance?

The legal status of the compound generally requires a prescription (℞). However, it is not commonly classified as a federally controlled substance in the U.S. or other major jurisdictions.


Q: Can Theodex impact kidney function?

Official regulatory documents advise that caution should be used when the medicine is administered to patients with pre-existing conditions such as renal impairment (reduced kidney function or disease).


Q: Does Theodex affect your mood or cause anxiety?

The potential risks documented in clinical trials include the occurrence of central nervous system side effects. Specifically, regulatory documentation mentions effects such as nervousness and restlessness.


Q: Are there any long-term effects of using Theodex for many years?

Long-term clinical trials have investigated the compound's safety profile when administered chronically for up to one year in individuals with asthma. Findings from these trials have noted that the drug was generally well tolerated and effective over this duration.


Q: What is the typical duration of treatment with Theodex?

The official product information specifies that this medicine is intended for long-term, continuous maintenance therapy. It is used to help manage chronic respiratory conditions on an ongoing basis.


Q: Can Theodex be used by children, according to official guidelines?

Official regulatory guidelines state the compound is not recommended for children under 6 years of age, as safety or effectiveness has not been established for this group. For children over 6 years of age, eligibility for use is described in regulatory documents.


Q: Does Theodex interact with alcohol?

Regulatory safety information often describes the interaction of this compound with alcohol as unknown. Due to limited definitive data, official resources often include a general statement regarding the consumption of alcohol with this compound.

How should Theodex be stored and disposed of?

Storage Requirements

Theodex (doxofylline) must be stored at or below 30 C (86 F) in a cool and dry place. The official labeling requires the medicine to be protected from light and directs that the container be kept tightly closed to maintain product stability. Exposure to moisture and excessive heat should be avoided to preserve the quality of the medication.

Child Safety and Disposal

It is a mandatory regulatory requirement to keep Theodex out of the reach and sight of children. To dispose of unused or expired tablets, the optimal option is to utilize an authorized drug take-back program or follow any specific disposal instructions provided with the original packaging. Unused medication should not be released into the environment or wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Theodex found in:

A-Z Index: